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Introduction
Avian sarcoma virus 17 (ASV 17)' is a retrovirus that induces progressively growing fibrosarcomas in chickens and transforms cultured chicken embryo fibroblasts into elongated refractile neoplastic cells (1) . The normal cellular homologue of the ASV 17 transforming gene is the c-jun protooncogene (2) (3) (4) . The protein product of c-jun is structurally and functionally similar to a component of the mammalian transcriptional activator AP-1 (5, 6) . Subsequent studies have demon-tosine; ASV, avian sarcoma virus; NBT, nitroblue tetrazolium; NSE, a-naphthyl acetate esterase; TPA, 12-O-tetradecanoylphorbol-1 3-acetate.
strated that c-jun is a member of a multigene family of mammalian transcription factors, which also includesjun-B, jun-D, c-fos, fos-B and fra-1 (reviewed in references [7] [8] [9] . Protein members ofthis family interact via a common structural motif identified as a leucine zipper. Dimerization of these proteins allows the DNA binding region to recognize and bind to the heptameric DNA consensus sequence TGAG/cTCA. Expression of the c-jun gene is an early response event during activation of fibroblasts and is rapidly activated by serum or phorbol esters (10) (11) (12) . Furthermore, c-jun expression is induced by a number of growth factors including platelet-derived growth factor (10) , fibroblast growth factor (10) , epidermal growth factor (13) , transforming growth factor-# (14) , tumor necrosis factor (15, 16) , nerve growth factor (17) , and IL 1 (18) . Moreover, c-jun protein increases transcription of the c-jun gene by an autoregulatory mechanism (19) .
l--D-Arabinofuranosylcytosine (ara-C) is one of the most effective agents in the treatment of human acute myelogenous leukemia (20) . The mechanism(s) of action of ara-C and the basis for selectivity against leukemic cells, however, remain unclear. Ara-C is a potent inhibitor of DNA replication (21, 22) . Studies with ara-C have demonstrated that inhibition of DNA synthesis is significantly related to the extent of drug incorporation into DNA (23) . Moreover, there is a highly significant relationship between the formation of (ara-C) DNA and loss of clonogenic survival (24, 25) . Ara-C also induces differentiation of mouse leukemic myeloblasts (26) . Similarly, exposure of the human HL-60 (27), ML-1 (28) , and U-937 (29) cell lines to ara-C results in the induction of terminal differentiation along the monocytic lineage. In this regard, induction ofU-937 cells by ara-C is associated with down regulation of c-myc transcripts as well as an increase in c-fos gene expression (29) .
There is presently little known about the mechanisms by which ara-C regulates gene expression. In this study, we monitored the effects of ara-C on the regulation of c-jun gene expression in human myeloid leukemia cells. We demonstrate that ara-C increases the level of c-jun transcripts in these cells and that this induction is regulated at the level oftranscription. HCl, pH 7.5).
Methods
Plasmid DNAs containing various cloned inserts were digested with restriction endonucleases as follows: (a) Results KG-I cells were treated with various concentrations of ara-C to determine the effects of this agent on cell growth. Although 10-7 M ara-C had partial growth inhibitory effects, proliferation was completely inhibited in the presence of 10-6 and IO-'
M drug (Fig. 1) . In contrast, exposure to IO-4 M ara-C for 72 h was associated with cell lethality (Fig. 1) . The effects of ara-C on phenotypic differentiation were also determined by moni- toring changes in histochemical staining. While 7.5% of untreated KG-I cells were NSE positive, 39.5% of these cells stained positively for NSE after 48 h of exposure to ara-C (Table I) . In contrast, ara-C treatment was associated with little, if any, change in the percentage of cells that reduced NBT (Table I) . These results suggest that ara-C induces KG-1 cells along the monocytic lineage. We next studied the effects of various concentrations of ara-C on c-jun gene expression in KG-1 cells. Northern blot analysis of KG-1 cellular RNA collected at 2 and 24 h of drug exposure is shown in Fig. 2 . c-jun transcripts were undetectable in untreated KG-1 cells, and exposure to 1O-7 or 10-6 M ara-C for 2 h had little effect on expression of this gene. In contrast, treatment with 10-5 M and lo-4 M ara-C for 2 h resulted in induction of 2.7-kb c-jun transcripts. Lower concentrations of ara-C (10-6 M) also induced c-jun expression after 24 h of treatment (Fig. 2) . Furthermore, the changes in c-jun mRNA levels were associated with little if any effect of ara-C on actin gene expression. These findings suggested that A ara-C The effects ofara-C on the kinetics ofc-jun expression were next studied using a cytostatic concentration of drug. c-jun transcripts reached maximal levels by 6-8 h of exposure to 5 X 10-6 M ara-C and declined by 10 h (Fig. 3 A) . Furthermore, c-jun mRNA levels remained elevated at 24 h of ara-C exposure before returning to that in control cells by 72 h (Fig. 3 B) . These findings were also associated with the absence of a detectable effect on actin gene expression. Similar studies were performed using serum-starved cells. KG-I cells were grown in 1% serum for 18 h and then exposed to ara-C. After 6 h, a significant increase in c-jun mRNA levels was observed in the absence of serum (Fig. 3 C) .
To determine the effects of cell cycle on induction of c-jun by ara-C, KG-I cells were treated with 5 X 10-6 M ara-C for varying times and analyzed by fluorescence flow cytometry.
While 53.4% of untreated KG-1 cells were in GI phase, 75.2% ofthese cells were in GI after 24 h of ara-C exposure (Table II) . KG-I cells were exposed to 5 X 10-6 M ara-C for the indicated times. The percentage of cells in GI, S, and G2/M phase was determined by fluorescence flow cytometry.
In contrast, the percentage of cells in S and G2/M phase decreased from .36 and 10.5% to 20.2 and 4.7%, respectively (Table II) . These results confirm that ara-C inhibits S-phase DNA synthesis and accumulates cells in the G1/S interphase.
Previous studies have demonstrated that exposure of human HL-60 and U-937 cells to ara-C results in the induction of terminal differentiation along the monocytic lineage (27, 29) . Thus, it was also ofinterest to determine the effects of ara-C on c-jun expression in other myeloid cell lines. Ara-C treatment was associated with increases in c-jun transcripts in U-937, THP-1, and HL-60 cells, although the relative levels of induction varied among the cell lines (Fig. 4) . These results indicate that ara-C induces c-jun expression in several human myeloid leukemia cell lines.
Run-on transcription assays were performed to determine whether transcriptional mechanisms are responsible for the effects of ara-C on c-jun expression. The actin gene was constitutively transcribed in KG-I cells and ara-C treatment had no effect on the transcription rate of this gene (Fig. 5) . A low level of c-jun gene transcription was detectable in untreated KG-1 cells. However, exposure to ara-C for 6 h was associated with a sixfold increase in c-jun gene transcription (Fig. 5) . Taken together, these results suggested that the induction of c-jun expression by ara-C is regulated by a transcriptional mechanism.
We and others have recently shown that treatment of human myeloid leukemia cells with phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), is associated with induction of c-jun transcripts (30, 34) was of interest to determine if the effects of TPA on c-jun mRNA could also be demonstrated in KG-I cells. In contrast to HL-60 cells, TPA had no detectable effect on c-jun mRNA levels in KG-1 cells (Fig. 6) . However, the combination of cycloheximide, an inhibitor of protein synthesis, and TPA for 4 h increased levels of c-jun by sixfold as compared with treatment with either cycloheximide or TPA alone (Fig. 5) . Similar studies were therefore performed to examine the effects of ara-C on c-jun expression in the absence of protein synthesis. KG-I cells were exposed to cycloheximide in the presence or absence of 5 X 10-6 M ara-C. Cycloheximide treatment alone for 1, 3, or 6 h had no detectable effect on c-jun mRNA levels (Fig. 7) . In contrast to the findings with TPA, treatment of KG-I cells with both ara-C and cycloheximide failed to superinduce c-jun mRNA levels compared to ara-C alone (Fig. 7) .
To further study the regulation of ara-C-induced c-jun RNA levels, KG-I cells were treated with 5 X 10-6 M ara-C for 6 h to induce c-jun expression and then exposed to actinomy- mRNA (Fig. 8) . The half-life of c-jun mRNA in KG-I cells as determined by densitometeric scanning was 42 min. Moreover, cycloheximide had little if any effect on the half-life of c-jun transcripts in these cells (data not shown). The stability of c-jun mRNA was also determined in both untreated and ara-C-treated U-937 cells. Untreated U-937 exposed to actinomycin D for varying times resulted in a decrease in the level of constitutively expressed c-jun transcripts. The half-life of c-jun mRNA was determined by densitometric scanning was 30 min. U-937 cells were also treated with 5 X 10-6 M ara-C for 6 h to induce c-jun expression and then exposed to actinomycin D to inhibit further transcription. Under these conditions, the half-life of c-jun mRNA was determined to be 30 min. Taken together, these results suggest that ara-C has little if any effect on the stability of c-jun mRNA.
Discussion
In the present study, we have demonstrated that ara-C increases c-jun RNA levels in KG-I cells in a concentration-and time-dependent manner. Analysis of relative rates of gene transcription showed that ara-C treatment of KG-I cells is associated with significant increases in c-jun gene transcription. These results indicate that the induction ofc-jun by ara-C is mediated, at least in part, by a transcriptional mechanism. Regulation of c-jun expression by transcriptional mechanisms has also been described for serum, phorbol esters, and certain growth factors. A rapid increase in c-jun transcription occurs during the GO/GI transition in mouse fibroblasts (I 1). Because ara-C inhibits S phase DNA synthesis and accumulates cells at the G,/S interphase, the present findings might be explained by cell cycle-related events. However, similar exposures to cytostatic concentrations of aphidicolin, an inhibitor of DNA polymerase a (35) , had no detectable effect on c-jun expression (data not shown).
The induction of c-jun RNA after treatment with TPA or growth factors in certain cell lines is also regulated by posttranscriptional mechanisms. The stabilization of c-jun transcripts following protein synthesis inhibition has suggested the presence of a labile ribonuclease. Indeed, the 3Y-untranslated region of the c-jun transcript contains an AU-rich sequence that has been implicated as a recognition site for the degradation of mRNAs coding for a variety of protooncogenes and growth factors (36, 37) . We have found that treatment ofKG-1 cells with both TPA and cycloheximide is also associated with superinduction of c-jun mRNA levels. In contrast, treatment of KG-l cells with ara-C and cycloheximide showed no increase in levels of c-jun mRNA compared with that obtained during treatment with ara-C alone. These results suggest that induction of c-jun expression by ara-C differs from induction by TPA and that there are at least two separate mechanisms for regulating c-jun mRNA levels in KG-1 cells.
The molecular mechanism by which ara-C increases c-jun transcripts is unclear. The active metabolite, ara-CTP incorporates into DNA and is a potent inhibitor ofDNA replication in eukaryotic cells (23) (24) (25) . Ara-C-induced cytotoxicity correlates significantly with the amount of ara-C incorporation into cellular DNA (24, 25) . The incorporated ara-C residue alters reactivity of the 3' terminus, slows chain elongation and results in DNA fragmentation (23) . Moreover, the relative chain-terminating effects of ara-C are dependent on the concentration of drug and sequence of the elongating DNA strand (38, 39). Although ara-C might incorporate into the promoter region of the c-jun gene and thereby possibly alter rates of transcription, this mechanism would appear to be an unlikely explanation for the marked induction of this gene. Another possibility might include ara-C-induced decreases in the expression of a trans-acting factor involved in the negative regulation of c-jun transcription. The cis-acting elements in the c-jun promoter have been defined and thus additional studies are now needed to define more precisely the mechanism whereby ara-C induces transcription of this gene.
Finally, the increase in c-jun gene expression by ara-C may in turn induce other genes with a c-jun/AP-1 binding site. Treatment of myeloid leukemia cells with ara-C is associated with decreases in c-myc mRNA levels, as well as an increase in c-fos gene expression (29) . In this regard, c-jun/AP-1-like sequences in the 5' regulatory region of c-myc have been implicated in the down regulation of this gene (40, 41) . Thus, the transient increase in c-jun expression by ara-C may initiate specific transcriptional events necessary for the regulation of certain other genes associated with ara-C-induced myeloid differentiation.
